ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 42 filers reported holding ADC THERAPEUTICS SA in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $10 | -99.2% | 6 | -99.5% | 0.00% | – |
Q3 2023 | $1,179 | -60.3% | 1,315 | -4.8% | 0.00% | – |
Q2 2023 | $2,971 | -98.1% | 1,382 | -98.3% | 0.00% | – |
Q1 2023 | $157,732 | -99.1% | 80,888 | -98.3% | 0.00% | -100.0% |
Q4 2022 | $17,869,261 | -51.7% | 4,653,453 | -39.4% | 0.00% | -50.0% |
Q3 2022 | $36,985,000 | -39.4% | 7,673,137 | -0.1% | 0.00% | -33.3% |
Q2 2022 | $61,065,000 | -45.9% | 7,681,046 | 0.0% | 0.01% | -33.3% |
Q1 2022 | $112,835,000 | -27.2% | 7,681,046 | +0.1% | 0.01% | -18.2% |
Q4 2021 | $154,988,000 | -25.6% | 7,672,673 | 0.0% | 0.01% | -35.3% |
Q3 2021 | $208,390,000 | +11.5% | 7,672,673 | 0.0% | 0.02% | +13.3% |
Q2 2021 | $186,830,000 | -1.4% | 7,672,673 | -1.1% | 0.02% | -6.2% |
Q1 2021 | $189,460,000 | -23.7% | 7,761,585 | 0.0% | 0.02% | -27.3% |
Q4 2020 | $248,448,000 | -1.8% | 7,761,585 | +1.2% | 0.02% | -15.4% |
Q3 2020 | $253,085,000 | +3.1% | 7,671,585 | +46.3% | 0.03% | -3.7% |
Q2 2020 | $245,483,000 | – | 5,244,231 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 11,167,800 | $24,010,770 | 3.60% |
Sio Capital Management, LLC | 4,020,705 | $8,644,516 | 2.20% |
Redmile Group, LLC | 14,049,935 | $30,207,360 | 1.16% |
Vantage Consulting Group Inc | 885,520 | $1,903,868 | 1.10% |
Blue Owl Capital Holdings LP | 733,568 | $1,577,171 | 0.97% |
AlphaCentric Advisors LLC | 778,000 | $1,672,700 | 0.93% |
Affinity Asset Advisors, LLC | 600,000 | $1,290,000 | 0.45% |
GCM Grosvenor Holdings, LLC | 410,888 | $883,409 | 0.38% |
Indie Asset Partners, LLC | 93,839 | $201,754 | 0.22% |
Frazier Life Sciences Management, L.P. | 1,647,030 | $3,541,115 | 0.21% |